(Q33695764)

28 July 2017

1 reference

title

Muscarinic receptor ligands and their therapeutic potential (English)

1 reference

28 July 2017

Eglen RM

1

1 reference

28 July 2017

Choppin A

series ordinal

2

1 reference

28 July 2017

Dillon MP

series ordinal

3

1 reference

28 July 2017

Hegde S

series ordinal

4

1 reference

28 July 2017

1 August 1999

1 reference

Current Opinion in Chemical Biology

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

4

1 reference

28 July 2017

426-432

1 reference

Selective muscarinic receptor agonists and antagonists

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Potential role of muscarinic agonists in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Muscarinic agonists for the treatment of Alzheimer's disease: progress and perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

SCH 57790: a novel M2 receptor selective antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Urinary incontinence--where do we stand and where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

A case-control study to examine any association between idiopathic detrusor instability and gastrointestinal tract disorder, and between irritable bowel syndrome and urinary tract disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Morbidity and mortality from chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

1 reference

7 January 2021

Therapeutic approaches to chronic obstructive pulmonary disease: an emerging consensus

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Discovery & development of selective M3 antagonists for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

1 reference

7 January 2021

Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

Should inhaled anticholinergics be added to beta2 agonists for treating acute childhood and adolescent asthma? A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980063-5

7 January 2021

10.1016/S1367-5931(99)80063-5

Identifiers

DOI

1 reference

28 July 2017

1 reference